Travere Therapeutics slides after forecasting Q4 sales below estimates

Travere Therapeutics

13/01/2026 15:26

** Shares of drug developer Travere Therapeutics TVTX.O fall 25.9% to $25.58

** Company said late on Monday it expects total U.S. sales for Q4 to be about $127 million, below Wall Street estimates of $142.2 million - data compiled by LSEG

** For 2025, co expects total U.S. sales to be about $410 million vs estimates of $502.96 million

** Co to restart late-stage study of experimental therapy, pegtibatinase, in patients with rare metabolic disorder in Q1 2026

** TVTX said it responded to FDA requests for more data on Filspari’s benefit in focal segmental glomerulosclerosis patients, and the agency is reviewing those submissions

** As of last close, stock had risen 83.4% in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))